Xeris Pharmaceuticals (NASDAQ:XERS) issued its quarterly earnings data on Thursday. The company reported ($1.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.23) by $0.01, Fidelity Earnings reports. The business had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 107.65% and a negative net margin of 4,876.50%.
NASDAQ:XERS traded down $0.21 during midday trading on Friday, hitting $8.02. 109,200 shares of the company traded hands, compared to its average volume of 201,264. The firm’s fifty day moving average is $8.76 and its 200-day moving average is $10.50. Xeris Pharmaceuticals has a 12-month low of $6.85 and a 12-month high of $25.49. The firm has a market capitalization of $236.68 million, a P/E ratio of -1.61 and a beta of -0.49. The company has a current ratio of 6.00, a quick ratio of 6.00 and a debt-to-equity ratio of 0.39.
XERS has been the topic of several recent research reports. Royal Bank of Canada set a $18.00 price objective on Xeris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Finally, Mizuho restated a “buy” rating and set a $22.00 price target on shares of Xeris Pharmaceuticals in a report on Friday.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.